Business Description
Fennec Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA31447P1009
Compare
Compare
Traded in other countries / regions
FENC.USAFRX.CanadaRV41.Germany IPO Date
2001-06-04Description
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.43 | |||||
| Equity-to-Asset | -0.43 | |||||
| Debt-to-Equity | -2.66 | |||||
| Debt-to-EBITDA | -2.48 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -7 | |||||
| Beneish M-Score | 8.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 392.2 | |||||
| 3-Year EBITDA Growth Rate | 13.9 | |||||
| 3-Year EPS without NRI Growth Rate | 6.4 | |||||
| 3-Year FCF Growth Rate | -0.9 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.99 | |||||
| 9-Day RSI | 31.22 | |||||
| 14-Day RSI | 41.55 | |||||
| 6-1 Month Momentum % | 36.58 | |||||
| 12-1 Month Momentum % | 16.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.56 | |||||
| Quick Ratio | 3.27 | |||||
| Cash Ratio | 1.76 | |||||
| Days Inventory | 397.43 | |||||
| Days Sales Outstanding | 65.36 | |||||
| Days Payable | 876.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.3 | |||||
| Shareholder Yield % | -4.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.08 | |||||
| Operating Margin % | -61.27 | |||||
| Net Margin % | -75.69 | |||||
| FCF Margin % | -80.9 | |||||
| ROA % | -70.22 | |||||
| ROIC % | -659.7 | |||||
| ROC (Joel Greenblatt) % | -407.99 | |||||
| ROCE % | -70.02 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 32.57 | |||||
| PS Ratio | 12.83 | |||||
| EV-to-EBIT | -23.29 | |||||
| EV-to-EBITDA | -23.7 | |||||
| EV-to-Revenue | 13.91 | |||||
| EV-to-Forward-Revenue | 5.57 | |||||
| EV-to-FCF | -17.19 | |||||
| Earnings Yield (Greenblatt) % | -4.29 | |||||
| FCF Yield % | -6.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fennec Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 28.588 | ||
| EPS (TTM) (C$) | -0.823 | ||
| Beta | 0.92 | ||
| Volatility % | 51.53 | ||
| 14-Day RSI | 41.55 | ||
| 14-Day ATR (C$) | 0.179606 | ||
| 20-Day SMA (C$) | 14.54 | ||
| 12-1 Month Momentum % | 16.64 | ||
| 52-Week Range (C$) | 9.27 - 15.43 | ||
| Shares Outstanding (Mil) | 27.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fennec Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fennec Pharmaceuticals Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fennec Pharmaceuticals Inc Frequently Asked Questions
What is Fennec Pharmaceuticals Inc(TSX:FRX)'s stock price today?
The current price of TSX:FRX is C$13.77. The 52 week high of TSX:FRX is C$15.43 and 52 week low is C$9.27.
When is next earnings date of Fennec Pharmaceuticals Inc(TSX:FRX)?
The next earnings date of Fennec Pharmaceuticals Inc(TSX:FRX) is 2024-05-10 Est..
Does Fennec Pharmaceuticals Inc(TSX:FRX) pay dividends? If so, how much?
Fennec Pharmaceuticals Inc(TSX:FRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers